The stock of Cempra Inc (NASDAQ:CEMP) hit a new 52-week low and has $6.05 target or 13.00% below today’s $6.95 share price. The 5 months bearish chart indicates high risk for the $358.81M company. The 1-year low was reported on Nov, 7 by Barchart.com. If the $6.05 price target is reached, the company will be worth $46.65 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 13.62 million shares traded hands or 564.39% up from the average. Cempra Inc (NASDAQ:CEMP) has declined 58.65% since April 5, 2016 and is downtrending. It has underperformed by 60.61% the S&P500.
Cempra Inc (NASDAQ:CEMP) Ratings Coverage
Out of 11 analysts covering Cempra (NASDAQ:CEMP), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. Cempra has been the topic of 18 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, June 24 by Stifel Nicolaus. The stock of Cempra Inc (NASDAQ:CEMP) has “Neutral” rating given on Thursday, November 3 by JP Morgan. The firm has “Buy” rating given on Friday, October 23 by Stifel Nicolaus. The rating was maintained by Needham on Monday, November 7 with “Buy”. The rating was downgraded by Robert W. Baird on Wednesday, November 2 to “Underperform”. Raymond James initiated Cempra Inc (NASDAQ:CEMP) on Tuesday, September 13 with “Outperform” rating. Janney Capital initiated Cempra Inc (NASDAQ:CEMP) rating on Friday, December 11. Janney Capital has “Buy” rating and $43 price target. Jefferies maintained the shares of CEMP in a report on Tuesday, August 2 with “Buy” rating. Leerink Swann initiated Cempra Inc (NASDAQ:CEMP) on Tuesday, October 13 with “Mkt Perform” rating. The company was maintained on Tuesday, June 7 by Roth Capital.
According to Zacks Investment Research, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 2.27 in Q2 2016. Its up 0.72, from 1.55 in 2016Q1. The ratio increased, as 10 funds sold all Cempra Inc shares owned while 23 reduced positions. 14 funds bought stakes while 61 increased positions. They now own 39.80 million shares or 3.16% more from 38.58 million shares in 2016Q1.
Utd Serv Automobile Association last reported 0.01% of its portfolio in the stock. Belmont Global Advsrs reported 15,000 shares or 0.24% of all its holdings. General Amer Investors Co reported 514,409 shares or 0.88% of all its holdings. Weiss Multi holds 0.08% or 62,694 shares in its portfolio. Stifel Corp has 0.01% invested in the company for 91,666 shares. Bnp Paribas Arbitrage, a New York-based fund reported 1,610 shares. Abingworth Llp holds 383,935 shares or 6.63% of its portfolio. Quantitative Management Lc last reported 16,300 shares in the company. Perceptive Advsrs Ltd Liability Corp owns 170,000 shares or 0.19% of their US portfolio. Alpinvest Partners Bv accumulated 67,763 shares or 2.21% of the stock. Ellington Mgmt Group Llc accumulated 10,300 shares or 0.24% of the stock. Blackrock Institutional Trust Co Na owns 1.00 million shares or 0% of their US portfolio. Rhenman Prtn Asset Mngmt Ab accumulated 171,000 shares or 0.5% of the stock. Portolan Cap Mngmt Ltd Company holds 0.7% or 295,575 shares in its portfolio. Eventide Asset Mgmt Ltd Liability Corporation holds 0.19% or 184,900 shares in its portfolio.
More important recent Cempra Inc (NASDAQ:CEMP) news were published by: Fool.com which released: “Why Cempra Inc. Got Crushed Again” on November 02, 2016, also Fool.com published article titled: “Why Cempra Inc Got Crushed Today”, Schaeffersresearch.com published: “Buzz Stocks: Cempra Inc, Ionis Pharmaceuticals Inc, and LendingClub Corp” on November 07, 2016. More interesting news about Cempra Inc (NASDAQ:CEMP) was released by: Benzinga.com and their article: “16 Stocks Moving In Monday’s Pre-Market Session” with publication date: November 07, 2016.
CEMP Company Profile
Cempra, Inc., incorporated on May 16, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. The Firm also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.